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CASE PRESENTATION
The patient is a 74-year-old man with non-insulin-dependent diabetes,
chronic renal insufficiency, peripheral vascular disease, and hypertension.
Two weeks prior to admission, he suffered a non-Q-wave myocardial
infarction while out of town. On his return to Boston, he continued to
experience chest pain and was referred for cardiac catheterization.
On admission medications included acetylsalicylic acid, hydralazine,
nitroglycerin, furosemide, lisinopril, and glyburide. He denied using
nonsteroidal anti-inflammatory drugs or having symptoms of urinary
obstruction. Physical examination disclosed: blood pressure, 140/70 mm
Hg; weight, 65 kg; jugular venous distention, 8 cm; bibasilar rales; a II/VI
holosystolic murmur and S3 gallop; and 11 pretibial edema. No epigastric
bruit was heard. His peripheral pulses were diminished below the knees,
and no ischemic changes were obvious.
Laboratory studies on admission showed a serum creatinine of 3.0 mg/dl
(similar to baseline levels); BUN, 71 mg/dl; sodium, 136 mEq/liter;
potassium, 5.2 mEq/liter; bicarbonate, 22 mEq/liter; and glucose, 158
mg/dl. Urinalysis showed 11 protein and a bland sediment. The urine
sodium was 11 mEq/liter; urine potassium, 44 mEq/liter; urine osmolality,
289 mOsm/kg; and fractional sodium excretion, 0.3%.
The patient was given intravenous nitrates, heparin, and 0.45% saline at
80 cc/hr for 12 hours prior to undergoing cardiac catheterization on
hospital day 2; furosemide and lisinopril were continued. The study
demonstrated a tight stenosis in his circumflex artery. He continued to
have angina with EKG changes and returned to the catheterization
laboratory for placement of a stent on hospital day 4. The next day, a
routine urine culture was reported positive for Staphylococcus aureus and
treatment with oxacillin was initiated. At that time, his serum creatinine
was 3.6 mg/dl. The serum creatinine continued to rise on hospital day 6,
reaching 5.0 mg/dl on hospital day 8. At that time, a Foley catheter was
inserted, and peripheral eosinophilia of 12% was noted. Oxacillin was
discontinued.
Physical examination on day 8 was essentially unchanged from his
admission exam. He had no evidence of livido reticularis or distal cyanosis.
No skin rash or fever was present. He had no uremic symptoms or
electrolyte abnormalities. His urine output was 1200 cc on hospital day 9.
Urine sediment revealed 11 protein, granular casts, 10 to 15 white blood
cells and rare red blood cells per high-powered field, and no crystals. The
fractional sodium excretion was 0.2%.
On hospital day 10, the serum creatinine began to decrease, continuing
to fall over the subsequent 4 days until it reached his baseline level of 2.9
mg/dl. The eosinophilia resolved, and the patient left the hospital on day
14 without angina.
DISCUSSION
DR. RICHARD SOLOMON (Division of Nephrology, Joslin Diabetes
Center and the Beth Israel Deaconess Medical Center; Associate
Professor of Medicine, Harvard Medical School, Boston, Massachu-
setts, USA): This gentleman presents with a number of possible
causes for acute renal failure including atheromatous emboli and
drug-induced interstitial nephritis. However, I believe that con-
trast-medium-induced nephropathy is the most likely reason for
the deterioration in his renal function. Atheromatous emboli
often occur following cardiac catheterization, but they are usually
associated with more sustained changes in renal function. Patients
with atheromatous emboli frequently have peripheral stigmata of
embolization; these were not present in this patient. Drug-
induced interstitial nephritis is also unlikely; the serum creatinine
was rising prior to the institution of oxacillin. Atheromatous
emboli and allergic interstitial nephritis are both associated with
eosinophilia. In this case, the eosinophilia might have been drug
related. The time course of the renal failure, the characteristics of
the patient (including his medications), and the performance of
two contrast procedures within 48 hours of each other make
radiocontrast-medium-induced nephropathy (RCIN) the most
likely diagnosis.
Diagnostic and interventional procedures using radiocontrast
media are performed with increasing frequency, and the patient
population subjected to them is progressively older with more
co-morbid conditions. It is therefore not surprising that the
contribution of RCIN to all hospital-acquired acute renal failure
has increased from 5% in a 1977 study to 32% in a 1987 study [1,
2].
A variety of definitions of RCIN have been employed in the
literature. A proportional rise in serum creatinine, for example,
25% or 50%, or an absolute rise in serum creatinine, for example,
0.5 mg/dl or 1.0 mg/dl, or a combination of the two are most
widely used and referenced to the time after contrast exposure,
that is, within 48 or 72 hours. Recent reviews have described the
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incidence of RCIN, its clinical course, and its pathogenesis [3–5].
The outcome of RCIN, for example, increased length of hospital
stay, need for dialysis, and patient mortality, have received less
attention. In this Forum, I plan to describe the population at risk
for RCIN, review our understanding of the pathogenesis of RCIN,
and conclude with specific strategies for the prevention of RCIN.
In patients with RCIN, serum creatinine rises, by 24 hours in
perhaps 60% of patients and by 72 hours in more than 90%. A
return to baseline levels occurs over 7 to 10 days [6–10]. The
serum creatinine level peaks 4 to 5 days following exposure to
contrast medium [11]. The RCIN is non-oliguric in most patients
described in recent series. Examination of the urine sediment in
RCIN reveals granular casts without cellular elements and mini-
mal proteinuria. The urine sediment can be entirely bland.
Fractional sodium excretion is low in some but not all studies,
particularly in oliguric patients [12–14]. Interestingly, a prospec-
tive study by Schwab et al found that fractional sodium excretion
averaged less than 1% both in patients who developed RCIN and
in those who didn’t following exposure to contrast medium [15].
Risk factors
The incidence of RCIN depends on a number of factors (Table
1). Barrett has analyzed the prospective trials using multivariate
analysis and found that baseline renal insufficiency, diabetes,
heart failure, and dose of contrast media increase the risk of
RCIN [3]; pre-existing renal insufficiency is the most significant of
these factors. In every study comparing patients with and without
some degree of renal insufficiency, renal insufficiency increased
the likelihood of RCIN [9, 16–21]. In a prospective trial of 1144
patients undergoing cardiac catheterization, Davidson and co-
workers found that the risk began to increase with a serum
creatinine greater than 1.2 mg/dl and was exponential thereafter
[16]. Approximately 20% of patients with a serum creatinine of 2.0
mg/dl prior to contrast medium exposure developed RCIN. An
increasing incidence of RCIN with high serum creatinine levels
has been reported by others [17] and accounts for the wide range
of RCIN reported in the literature. In the absence of renal
insufficiency, RCIN is infrequent, occurring in less than 10% of
patients in recent large prospective trials [15, 16, 22].
Diabetes is also a risk factor for RCIN. In diabetic patients
without renal insufficiency, the risk is similar to the non-diabetic
group [16, 19, 20, 22–27]. However, the combination of diabetes
and renal insufficiency increases the risk for RCIN at least twofold
compared to that expected from the renal insufficiency alone [10,
19, 22, 28]. This synergism does not depend on the route of
administration of the contrast agent or whether high- versus
low-osmolality media were used (see review by Rudnick et al [5]).
Indeed, diabetic patients with renal insufficiency often develop
oliguria and require dialysis [7, 10, 29–31]. This interaction
between diabetes and renal insufficiency might reflect abnormal-
ities of renal blood flow and endothelial cell function in diabetes,
as I will discuss later.
Congestive heart failure has been found to be an independent
risk factor in some [17, 21, 26, 32, 33] but not all [16, 25] studies.
Many of these patients were taking diuretics prior to contrast
medium exposure or were inadequately hydrated for fear of
precipitating pulmonary edema. Thus, intravascular volume de-
pletion and activation of renal vasoconstrictive mechanisms might
have played a role. In many of the animal models used to study the
pathogenesis of RCIN, volume depletion, induced by a low-salt
diet and diuretics, is required to produce RCIN.
The volume of contrast media administered also was a signifi-
cant risk factor in some but not all studies [17, 20, 25, 29, 30,
32–37]. A recent hemodynamic study in patients with renal
insufficiency found that only those who received greater than 135
ml of contrast medium had decrements in radionuclide renal
clearance lasting more than 3 hours [38]. For this reason, in
high-risk patients, such as those with renal insufficiency, diabetes,
and/or congestive heart failure, more-limited studies with lower
volumes of contrast are recommended.
Patients with multiple myeloma often are cited as having an
increased risk of RCIN [39, 40]. Potential mechanisms for this
increased risk include precipitation of Bence Jones and Tamm-
Horsfall proteins by contrast medium [41, 42]. However, most of
the risk probably is related to underlying renal insufficiency and/or
dehydration. A recent, retrospective review of studies involving
476 myeloma patients in fact failed to find any increased risk of
RCIN [43].
The consequences of RCIN are not negligible despite the high
frequency of recovery of renal function. In the presence of RCIN,
additional procedures that might adversely affect renal function,
for example, further exposure to contrast media or surgery, are
usually delayed until renal function has stabilized or begun to
return to baseline levels; this delay frequently results in increased
length of hospitalization. Dialysis is required in approximately
10% to 25% of patients, and occurs most frequently in patients
with oliguria [8, 44]. Failure of renal function to return to baseline
levels has been reported in as many as 30% of patients and usually
indicates additional insults, such as atheromatous emboli, sepsis,
or hypotension [8]. In a retrospective analysis, Levy and col-
leagues compared the outcome of 183 hospitalized patients who
developed RCIN with an age- and baseline renal function-
matched group undergoing a contrast procedure who didn’t
develop RCIN. The in-hospital mortality rate was 34% in patients
with RCIN versus 7% in those without RCIN. Even after adjust-
ing for co-morbid conditions, the odds ratio of dying was 5.5 for
those developing RCIN; indeed, most of the serious complica-
tions, such as sepsis, bleeding, respiratory failure, and delirium
developed after the onset of RCIN. The authors concluded that
RCIN increased the risk of developing severe non-renal compli-
cations that led to death [45]. On the other hand, more recent
prospective trials in high-risk patients exposed to contrast media,
including outpatients, have failed to find an increase in the
mortality rate [44]. In summary, RCIN is not benign. It can result
in increased hospital stay, occasional need for dialysis, and
perhaps increased mortality in inpatients with pre-existing co-
morbid conditions.
Table 1. Risk factors for RCIN
Renal insufficiency
Diabetes
Congestive heart failure
Volume depletion
Dose of contrast agent
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Pathogenesis
It is generally accepted that the pathogenesis of RCIN involves
ischemic injury to the medulla (see Ref. 46 for a review of the
pathogenesis of medullary ischemia). Attempts at characterizing
the hemodynamic changes have met with difficulty. All the animal
models involve experimental conditions that predispose to isch-
emic injury, such as hydropenia or volume depletion, administra-
tion of cyclo-oxygenase inhibitors, or transient interruption of
renal blood flow. We have known for years that the administration
of contrast media is associated with a biphasic hemodynamic
response in these models. Initial vasodilation lasting seconds
precedes a variable period of vasoconstriction with a fall in total
renal blood flow and a prolonged decrement in glomerular
filtration rate [46–48]. In volume-depleted animals, these hemo-
dynamic alterations are more pronounced and persist for as long
as 24 hours [49].
In humans, renal hemodynamics have been measured by many
investigators. Weisberg and colleagues have used renal vein
thermodilution catheters to measure global renal blood flow in
high-risk patients, that is, those with chronic renal insufficiency
with and without diabetes, who were undergoing cardiac cathe-
terization with high-osmolality contrast medium. These patients
all were well hydrated prior to study. This technique avoids
potential interference with PAH secretion by contrast medium,
although this effect seems to be small and transient [50]. Many of
these subjects developed renal insufficiency allowing for a corre-
lation with the renal hemodynamic changes. Contrast medium
infusion caused an immediate increase in total renal blood flow.
Mean arterial pressure did not change; therefore, renal vascular
resistance decreased. A further decrease in renal vascular resis-
tance and an increase in renal blood flow, averaging 176% of
baseline, occurred with a second dye load. These studies of global
renal blood flow were performed in the minutes immediately
following the contrast medium load. It is not known what hap-
pened to renal blood flow in the hours following the contrast
medium exposure [51].
In additional studies, these investigators administered vasodi-
latory agents, such as atrial natriuretic peptide, dopamine, or
mannitol immediately before the admininistration of contrast
medium. Each vasodilator increased renal blood flow before
contrast medium exposure and renal blood flow increased further
following administration of the contrast medium [52, 53]. To the
investigators’ surprise, this hyperemic response in the presence of
contrast medium was associated with an increased incidence of
RCIN. Patients who developed RCIN had a lower baseline renal
blood flow and a greater increase in renal blood flow in response
to the vasodilatory agents. Most of these patients were diabetic.
The filtration fraction was higher in the patients with lower
baseline renal blood flow. This suggests the presence of efferent
arteriolar vasoconstriction [54].
These studies indicate that an immediate decrease in renal
blood flow does not occur in well-hydrated patients undergoing
exposure to contrast medium, but the studies do not address the
changes in renal blood flow that can follow after some latent
period. More recent studies were performed by Russo and
coworkers in patients with chronic renal insufficiency during water
diuresis and following intravenous administration of either high-
or low-osmolality contrast medium [55]. With the high-osmolality
medium, renal blood flow and inulin clearance fell at 20 minutes
following exposure and were still falling at 120 minutes after
administration of the contrast medium. At this time point, the
renal blood flow had fallen to 65% of the baseline value. With the
low-osmolality medium, renal blood flow fell only at the 120-
minute point, and the magnitude of the fall was lower (approxi-
mately 21% of baseline). Only the patients exposed to the
high-osmolality medium developed RCIN.
These results suggest that the hemodynamic response to con-
trast medium in humans is biphasic, with an initial vasodilatory
phase followed by a more prolonged vasoconstrictive phase.
Development of RCIN is associated with a greater fall in total
renal blood flow than that of patients who are exposed to contrast
medium but don’t develop RCIN [55]. The association of an
exaggerated initial vasodilatory phase with RCIN might reflect
abnormal intrarenal distribution of blood flow. For example, a
decrease in vascular resistance in the cortex without a parallel
decrease in vascular resistance in the medulla might lead to a
“stealing” of blood from the medulla. In addition, vasodilators
might increase glomerular filtration rate and delivery of sodium to
the loop of Henle resulting in an increase in oxygen consumption.
A fall in medullary oxygen tension following administration of
atrial natriuretic peptide presumably occurs on this basis [56].
Brezis’ group has provided evidence that contrast media do
indeed produce medullary ischemia. They implanted oxygen-
sensitive microelectrodes in the cortex and medulla of rat kidneys
in vivo. Oxygen tension was significantly lower in the medulla
compared to the cortex. This difference in oxygen tension results,
in part, from the high rate of oxygen consumption in the loop of
Henle associated with ion transport. Interstitial oxygen tension in
the medulla is increased to levels found in the cortex by inhibition
of loop transport with furosemide. In a salt-depleted, indometh-
acin-treated, uninephrectomized animal, exposure to contrast
medium produced a decrease in medullary oxygen tension from 27
mm Hg to 9 mm Hg lasting for at least 60 minutes [57]. In other
experiments with indomethacin-treated rats, medullary blood flow
also decreased with contrast medium infusion [58]. The decrease
in blood flow and oxygen tension caused necrosis of the medullary
thick ascending limbs and a rise in serum creatinine on subse-
quent days.
What factors contribute to the medullary ischemia? Filtration
of the high solute load of contrast medium would be expected to
increase delivery of sodium and chloride to the thick ascending
limb of Henle. This increase would promote increased oxygen
consumption. However, the fall in medullary interstitial oxygen
tension is more than can be accounted for by increased consump-
tion alone. A decrease in medullary oxygen delivery, that is, a
decrease in blood flow, also must occur. Activation of tubuloglo-
merular feedback might be one mechanism that shifts the balance
between vasoconstrictive and vasodilatory forces [59]. A number
of potential vasoconstrictive factors–angiotensin, endothelin,
adenosine, thromboxane–all have been implicated in the patho-
genesis of RCIN.
Early studies suggested a role for the renin-angiotensin system.
Blockade of angiotensin II’s effects by producing tachyphylaxis
[46] or by introducing specific receptor blockers [47] partially
diminished the vasoconstrictive response to contrast media in
animals. Likewise, infusion of angiotensin II exacerbated the
injury in a rat model [60]. Unfortunately, no controlled trials in
humans have tested the efficacy of blockade of the renin-angio-
tensin system. A small prospective study in patients with chronic
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renal insufficiency found that a single dose of captopril given 20
minutes prior to contrast medium exposure reduced the decre-
ment in renal blood flow and glomerular filtration rate measured
120 minutes later [55]. The incidence of RCIN was not reported
in this study.
Endothelin, the 21 amino acid vasoconstrictor peptide, has
received a lot of attention recently. We know of three endothelin
peptides–ET1, ET2, and ET3–and at least two receptors–ETa and
ETb. Endothelin, derived from renal endothelial and mesangial
cells, acts locally to produce intense and long-lasting vasoconstric-
tion. The evidence for a role of endothelin in RCIN derives from
in-vitro as well as in-vivo experiments (Fig. 1). A variety of
contrast media release endothelin from cultured endothelial cells
in vitro [61]. The mechanism is unclear, but it is not simply an
effect of hypertonicity [61, 62]. In addition, endothelin mRNA
also is increased by contrast media; thus the release of endothelin
is not a toxic effect of the contrast medium [62]. In vivo,
circulating endothelin increases within minutes following expo-
sure to the contrast medium and remains elevated for hours [63].
Urinary endothelin also increases [63]. Although endothelin is
small enough to be filtered, proximal tubule brush border enzymes
would normally destroy most of the filtered endothelin. Indeed,
only a small fraction of administered 125I-Et appears in the urine
intact in normal animals [64]. Therefore, the increased urinary
endothelin suggests a renal origin of the endothelin. An alterna-
tive view is that the increased endothelin reflects contrast-medi-
um-induced damage to the proximal tubule, with filtered endo-
thelin appearing in the urine. This possibility is supported by a
correlation between urinary endothelin and markers of proximal
tubule damage, such as N-acetyl-beta-D-glucosaminidase (NAG)
and alpha 1-microglobulin [65]. The time course of endothelin
release coincides with the changes in renal hemodynamics in some
but not all studies [55]. In addition, a correlation exists between
the amount of endothelin released from cultured cells on the one
hand, and renal vasoconstriction and degree of morphologic
damage to the renal medulla in vivo on the other [66].
Endothelin’s role in the pathogenesis of RCIN also is suggested
by animal experiments in which an antagonist of the endothelin
receptor is infused prior to administration of a contrast medium.
The endothelin receptor antagonist prevents the decline in renal
blood flow seen in the absence of the antagonist [67–69] and also
prevents the subsequent rise in serum creatinine. A multicenter
clinical trial of an ETa receptor antagonist in patients with
elevated serum creatinine levels undergoing cardiac angiography
is in progress.
Adenosine, released by cells as a consequence of the metabo-
lism of ATP, also has been implicated in the pathogenesis of
RCIN. In some vascular beds, adenosine is vasodilatory; in other
vascular beds, for example, coronary and renal, adenosine is
vasoconstrictive. The vasoconstrictive effect of adenosine on renal
blood flow can be significantly reduced by theophylline [70].
Within the kidney, adenosine can have different effects on
medullary and cortical blood flow that depend on different
adenosine receptors. For example, in the rat, adenosine produces
cortical vasoconstriction through A1 receptors but produces med-
ullary vasodilation through A2 receptors [71]. Selective inhibition
of the A1 receptor markedly reduces contrast-medium-induced
reductions in renal blood flow and inulin clearance in animal
models [72]. In addition, adenosine might mediate tubuloglo-
merular feedback [73, 74]. Osmotic diuresis leads to an increase in
solute at the macula densa and release of adenosine; afferent
vasoconstriction follows, which reduces renal blood flow and
glomerular filtration [75]. The infusion of theophylline, an aden-
osine receptor antagonist, prevents the reduction in global renal
blood flow; dipyridamole, an inhibitor of adenosine re-uptake,
exacerbates the reduction in renal blood flow produced by con-
trast medium [70, 75, 76]. In humans, administration of contrast
medium increases urinary adenosine [76]. The administration of
both oral and intravenous theophylline prior to contrast medium
attenuates the decrease in renal blood flow (PAH clearance) and
glomerular filtration rate in patients with normal and reduced
renal function [76, 77].
Animal experiments have suggested that derangements in va-
sodilatory systems also contribute to contrast-medium-induced
renal dysfunction. Pharmacologic inhibition of the production of
vasodilatory prostaglandins and nitric oxide increases contrast
nephrotoxicity [58]. Pretreatment with L-NAME, a nitric oxide
synthase inhibitor, converts an initial vasodilatory response fol-
lowing contrast medium exposure to vasoconstriction in the renal
medulla; this change lasts for at least one hour. It is likely that
these maneuvers perturb the already precarious balance between
oxygen delivery and oxygen consumption in the renal medulla
[78]. The subsequent exposure to the contrast medium is the “last
straw,” which makes the vulnerable medulla succumb to ischemic
injury. Release of vasodilatory substances decreases with endo-
thelial injury and in patients with endothelial dysfunction from
diabetes, hypertension, or atherosclerotic vascular disease; these
observations might account for the increased risk of RCIN in
these patients.
A role for reactive oxygen species can be found in animal
studies, which document increased lipid peroxidation following
contrast medium exposure. The administration of catalase [49] or
superoxide dismutase [79] or the chelation of iron with deferox-
amine [80] can ameliorate the hemodynamic and functional
alterations induced by contrast media. These studies suggest that
reactive oxygen species play a pathophysiologic role in RCIN.
Whether all contrast media should be lumped together as
equally nephrotoxic is still controversial. Animal experiments
suggested that the osmolar load was of importance in determining
Saline
Iothalamate
Ioxaglate
Iohexol
Hypertonic saline
Hypertonic glucose
Hypertonic mannitol
0                         50                   100
Plasma endothelin, fmol/ml
Fig. 1. Radiocontrast media elevate plasma endothelin levels in vivo.
This effect is not related to the osmolality of the contrast medium and
does not occur with infusion of hypertonic saline, glucose, or mannitol.
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the reduction in renal function [8]. Hypertonic contrast media as
well as hypertonic saline infused into the renal artery reduced
renal blood flow in animals [46, 81]. High-osmolality contrast
media reduce renal blood flow in humans to a much greater extent
than do low-osmolality agents [82]. Some contrast media appear
to increase endothelin release more than others [66]. I will discuss
clinical trials of low- versus high-osmolality agents in a moment.
In addition to ischemia based on the hemodynamic changes I
have mentioned, evidence also indicates that contrast media are
directly toxic to renal tubular cells. In vitro, incubation of proximal
tubules with contrast media altered cellular metabolism, caused
release of intracellular enzymes, and produced histologic changes
consistent with toxicity [83]. In human studies, a variety of
proximal tubular enzymes, such as NAG, a lysosomal enzyme, and
alanine aminopeptidase (AAP), an enzyme associated with the
brush border, are released into the urine following contrast
medium exposure [84–87]. Small-molecular-weight proteins, such
as alpha-1-microglobulin and beta-2-microglobulin, which are
normally filtered and reabsorbed in the proximal tubules, also are
excreted in increased amounts following contrast medium expo-
sure [88]. The enzymuria and microproteinuria, found in all
subjects regardless of whether they develop RCIN, generally
abate within 24 hours. Although some reports suggest that low
osmolality contrast media produce less enzymuria, this observa-
tion has not been confirmed in other studies [89–91]. There does
not appear to be any value in monitoring these urinary abnormal-
ities in patients undergoing contrast studies.
Finally, tubular obstruction might play a role in the pathogen-
esis of RCIN in some patients. Contrast medium increases urate
excretion in the initial hours following exposure [92, 93]. In the
presence of dehydration, such an increase could contribute to
urate precipitation and intratubular obstruction. This mechanism
was probably more relevant in the past, when hydropenic condi-
tions often were used to enhance the radiographic quality of
urographic studies.
In summary, the evidence favors medullary ischemia as a
central pathophysiologic factor in the development of RCIN (Fig.
2). Mediators of this medullary ischemia are unknown. Shunting
of blood to the cortex (a medullary “steal syndrome”) might be a
final common pathway induced by an imbalance of vasodilatory
and vasoconstrictor forces operating independently in the cortex
and medulla. Thus any alteration in prostaglandin, nitric oxide,
endothelin, or adenosine metabolism could contribute to the
medullary ischemia. Indeed, the occurrence of RCIN need not
proceed through an identical pathophysiologic pathway in all
patients. In addition, patients with endothelial cell dysfunction,
for example, patients with diabetes, atherosclerosis, and hyper-
tension, might have increased sensitivity to contrast media on this
basis.
Prevention
Strategies for preventing RCIN are intuitively attractive. This is
one form of renal insult in which the clinician has an opportunity
for prevention. Alternative means of imaging should be sought
whenever the risks of RCIN are high. Newer technologies,
including CO2 arteriography and magnetic resonance angiogra-
phy, offer adequate imaging of some vascular systems without the
risk of contrast medium exposure. When contrast medium is
required, a minimum dose should be used. For example, routine
ventriculograms can be avoided in patients undergoing coronary
catheterization, thus reducing the contrast medium load. Like-
wise, many institutions would delay contrast-requiring therapeutic
interventions, for example, vascular stenting, until the first con-
trast load used for diagnostic studies had been successfully
tolerated.
The development of low-osmolality contrast medium was an-
ticipated to reduce the incidence of RCIN. But initial trials did
not find a benefit when low-osmolality agents were compared with
high-osmolality agents [15, 19, 34, 94]. These trials included
well-hydrated patients, and the incidence of RCIN was less than
12%, even in the patients with renal insufficiency. Rudnick and
associates performed a large prospective randomized trial involv-
ing 1196 patients, of whom 192 had various degrees of renal
insufficiency prior to contrast medium exposure (Fig. 3) [22].
These researchers demonstrated no benefit of low-osmolality
agents in diabetic and non-diabetic patients with normal renal
function, defined as a serum creatinine less than 1.6 ml/dl.
However, in patients with serum creatinine levels greater than 1.6
mg/dl before contrast medium exposure, low-osmolality contrast
medium reduced the incidence of RCIN from 36% to 21%, a
significant difference. The effect was seen both in diabetics and
non-diabetics with renal insufficiency. A meta-analysis of all
studies performed prior to the Rudnick trial also suggested a 50%
reduction in the incidence of RCIN in patients with underlying
renal insufficiency [95].
Sporadic reports of the benefits of diuretics, vasodilators,
hydration, and pharmacologic inhibitors of potential vasoconstric-
tors have filled the literature for the past 30 years. Many of these
strategies have now been subjected to prospective controlled
trials. Some trials are still underway.
Hydration with intravenous fluids prior to contrast medium
exposure has become the standard means of preventing RCIN. As
I noted, most animal models of RCIN employ volume-depletion
strategies, and pretreatment with saline is effective in prevention
of functional and histologic abnormalities following contrast
medium exposure [96]. Retrospective and uncontrolled clinical
studies also suggested a benefit of hydration [97–99].
We conducted a prospective randomized trial in 76 patients
Radiocontrast
media
Renal
ischemia
Nephro-
toxicity
Radiocontrast-induced
nephropathy
Vulnerable kidney
Renal insufficiency
Congestive heart failure
Volume depletion
Endothelial dysfunction
Diabetes, NSAIDS
Fig. 2. Pathophysiology of radiocontrast-medium-induced acute renal
insufficiency. Radiocontrast medium has both direct nephrotoxic and
intrarenal hemodynamic effects, which, in the presence of a vulnerable
kidney, lead to acute renal failure. Diseases and pathophysiologic pro-
cesses such as diabetes, congestive heart failure, volume depletion, and
renal insufficiency are important conditions increasing the vulnerability of
the kidney to radiocontrast-medium-induced injury.
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with renal insufficiency who were scheduled for cardiac catheter-
ization (Fig. 4). All patients received 0.45% NaCl solution at a
rate of 1 ml/kg/min for 12 hours before and 12 hours after contrast
medium exposure. One-third of the patients also received 80 mg
furosemide 30 minutes before contrast medium exposure, and an
additional one-third received 50 g of mannitol 60 minutes before
administration of the contrast medium. The overall incidence of
RCIN in this high-risk group (average serum creatinine of 2.1
mg/dl, 50% diabetic) was 26%, comparable to previously reported
experiences. However, the 0.45% saline alone group had an
incidence of only 11% compared to 26% for the mannitol group
and 46% for the group receiving furosemide. These significant
differences were not explained by variations in body fluid balance
or evidence of dehydration in the mannitol or furosemide groups.
Differences in the use of low- and high-osmolality contrast
medium, calcium-channel blockers, and other vasoactive drugs
also could not explain the results [28]. A prospective randomized
trial of furosemide (dose of 1.5 mg/kg given 30 minutes before
contrast medium exposure) versus 6 ml/kg/hr of lactated Ringer’s
solution for 4 hours showed similar results. The furosemide-
treated group had a significant increase in serum creatinine 24
hours after contrast-medium exposure compared to the saline-
treated group [100]. The furosemide-treated patients also lost
weight compared to the saline-treated patients; this difference
suggested that volume depletion occurred as a result of the
furosemide administration. In another prospective randomized
trial in patients with chronic renal insufficiency, saline hydration
decreased the incidence of RCIN compared to groups hydrated
similarly but given mannitol either before or after contrast
medium exposure [101].
Vasodilatory drugs have been used to counteract contrast-
induced renal vasoconstriction. However, the data from Weisberg
and colleagues might predict that this approach is a two-edged
sword [54]. Reductions in systemic blood pressure and/or prefer-
ential vasodilation of the cortical circulation could further com-
promise the medullary circulation. This indeed seems to be the
case in patients with diabetes [54]. Prospective trials in humans
generally have been unrewarding. The intra-arterial infusion of
atrial natriuretic peptide for 15 minutes before and 30 minutes
after arteriography completely prevented the fall in creatinine
clearance at 24 to 36 hours after contrast medium exposure in
patients with renal insufficiency [102]. However, a prospective
randomized trial has been performed with intravenous atrial
natriuretic peptide in a group of high-risk patients (247 patients
with a mean serum creatinine of 2.1 mg/dl). The peptide was given
prior to and for one hour after administration of contrast medium.
This trial has not yet been fully reported, but a beneficial result
was not found (Robin Allgren, M.D., Scios, Inc., personal com-
munication). It is possible that the short duration of treatment
with the peptide and the relatively low incidence of RCIN in the
entire study affected the results.
Two prospective trials, one with a randomized control group,
have found that dopamine, 2.5 to 3.0 mg/kg/min, given before and
12 to 24 hours after contrast medium exposure, completely
prevented RCIN in patients with mild renal insufficiency [103,
104]. In the control study, patients were well hydrated and did not
receive diuretics [104].
A small trial of intravenous theophylline, an adenosine receptor
antagonist, failed to show a benefit, but the doses used were quite
low [105]. More recently, intravenous theophylline, 5 mg/kg,
administered 45 minutes prior to contrast medium exposure,
prevented the fall in inulin clearance measured 48 hours after
contrast medium administration. The protective effect was seen in
patients both with normal and reduced basal renal function [77].
The effect was not statistically significant in the patients with
reduced renal function because of the small numbers. A trial of
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Fig. 4. Incidence of radiocontrast-medium-induced nephropathy (RCIN)
in 76 patients with renal insufficiency (serum creatinine > 1.5 mg/dl)
prospectively randomized to 0.45% saline volume expansion alone, saline
plus mannitol, or saline plus furosemide. RCIN occurred more frequently
in patients with diabetes and renal insufficiency. Saline alone provided
significantly better prophylaxis than did either mannitol or furosemide.
Symbols are: (M) non-diabetic; (f) diabetic. (From Ref. 28; used with
permission.)
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Fig. 3. The incidence of radiocontrast-induced nephropathy (RCIN) in
1196 patients prospectively randomized to low- (M) versus high- (f)
osmolar radiocontrast media. The patients were divided into groups on
the basis of a pre-contrast-procedure serum creatinine concentration of $
1.5 mg/dl (RI) and diabetes mellitus (DM). Only the patients with renal
insufficiency experienced a significant incidence of RCIN. The incidence
was higher in patients with diabetes and renal insufficiency. Low-osmolar
radiocontrast medium significantly reduced the incidence of RCIN in
patients with renal insufficiency both with and without diabetes mellitus.
(From Ref. 22; used with permission.)
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oral theophylline, 2.88 mg/kg given every 12 hours for 48 hours
beginning at least one hour prior to contrast medium exposure,
has been reported in 93 patients with chronic renal insufficiency.
Theophylline partially prevented the fall in creatinine clearance
measured 24 and 48 hours following administration of the contrast
medium [76].
While intravenous saline and/or vasodilatory agents with ac-
tions in the renal microcirculation offer an opportunity to directly
attack one of the prime pathophysiologic factors accounting for
RCIN, these agents are relatively impractical. In the managed
care environment, it is difficult to justify admission to the hospital
prior to angiography for the purpose of administering intravenous
fluids. The need for a monitored setting for some of the pharma-
cologic agents makes these approaches prohibitively expensive. It
would be valuable to know whether a shorter infusion of saline,
for example 3 hours at 100 ml/hr, provides the same prophylaxis as
the 12-hour infusion. At least in an animal model, a one-hour
saline infusion was not effective in preventing RCIN, although the
addition of saline to drinking water for one week was protective
[106].
Oral agents that can be taken by outpatients offer an attractive
alternative to the more expensive intravenous therapies. I have
already mentioned the small trial with oral theophylline [76].
Calcium-channel blockers inhibit vasoconstriction induced by
most of the presumed vasoconstrictors implicated in RCIN.
Administration of calcium-channel blockers prior to contrast-
medium exposure minimizes the vasoconstrictive response in
animals [70] and in humans [82].
Use of calcium-channel blockers has not reduced the incidence
of RCIN in retrospective trials of patients exposed to contrast
media [16, 29, 103, 107]. Small prospective trials have found that
calcium-channel blockers attenuated the reduction in glomerular
filtration following contrast medium exposure [108–110]. The
only trial reporting on the incidence of RCIN found no benefit,
however [88]. A larger trial with high-risk patients is clearly
needed. Until such data are available, the routine use of calcium-
channel blockers prior to administration of contrast medium
cannot be recommended. We do, however, recommend that
patients taking such agents continue their use prior to contrast
studies.
Finally, some groups have used dialysis to remove the contrast
medium. Both peritoneal and hemodialysis remove substantial
amounts of the contrast medium (50% to 90% of the dose);
hemodialysis is more effective [111–113]. When dialysis was
instituted within 1 to 3 hours following the exposure to a contrast
medium, RCIN was not observed in 13 patients whose average
serum creatinine was 4.5 mg/dl [112].
What recommendations can be made to protect patients from
RCIN? First, all patients scheduled for arteriography should have
their serum creatinine measured. A recent survey suggests that
there is much variability in this practice [114]. Patients without
renal insufficiency are at very low risk (5% to 10%) even if they
are diabetic. Adequate hydration is probably all that is necessary
for these patients. This practice includes discontinuation of di-
uretics 24 hours before elective exposure to a contrast medium
and the use of intravenous fluids in patients who are volume
depleted for any reason. In high-risk patients, that is, those with
an elevated serum creatinine level, particularly if they are dia-
betic, low-osmolality contrast media can be justified under certain
circumstances, for example, patients who are close to needing
dialysis (serum creatinine greater than 5 mg/dl) and hospitalized
patients who have multiple risk factors. All these patients should
be appropriately treated to avoid volume depletion; that is, they
should be given intravenous hydration prior to contrast medium
exposure and diuretics should be discontinued. We currently
recommend 0.45% saline at 1 ml/kg/min for at least 6 hours prior
to contrast-medium administration. We are not sure how long
before exposure we need to institute these measures. Volume
repletion with its attendant downregulation of renal vasoconstric-
tive mechanisms is the goal. This downregulation possibly is
achieved within hours of restoring the extracellular volume and
discontinuing diuretics.
The U.S. Food and Drug Adminstration (FDA) issued a
warning cautioning against the use of contrast medium in patients
who are taking metformin. Metformin is cleared entirely by renal
secretion. In the presence of renal insufficiency, increased serum
metformin levels have caused lactic acidosis and death [115]. Of
the 110 cases of metformin-induced lactic acidosis in the litera-
ture, 7 have occurred in association with RCIN [116]. It has been
recommended that metformin be discontinued for 48 hours
before contrast-medium exposure, and that its use be resumed
only when renal function is known to be at baseline.
Treatment of established RCIN
We have little data on the management of established RCIN. In
a prospective randomized trial of atrial natriuretic peptide treat-
ment for acute renal failure, a subgroup of patients with RCIN
was studied [44]. Of these 65 patients, 20 required dialysis within
21 days after exposure to a contrast medium. Atrial natriuretic
peptide did not reduce the overall need for dialysis, except in the
patients who were oliguric.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts): Rick, thank you very much for
your superb review. You mentioned that data from Schwab
showed low fractional sodium excretion both in patients who did
and those who did not develop radiocontrast-induced acute renal
failure. Does one see that same reduction in fractional sodium
excretion if low osmolar agents are used?
DR. SOLOMON: A low fractional excretion of sodium in RCIN
was first reported by Fang et al in 1980 [13], prior to the
widespread use of low-osmolality contrast medium. In the study
by Schwab’s group, the median fractional excretion of sodium was
reported for the groups that received diatrizoate (1500 mOsm/kg)
or iopamidol (796 mOsm/kg) [15]. In both groups, the fractional
excretion of sodium was less than 1% and was low both in those
who developed RCIN and in those who did not [15].
DR. HARRINGTON: Why did you choose to study the use of
half-normal saline rather than normal saline?
DR. SOLOMON: The choice was based upon a desire to produce
both volume expansion and a large volume of dilute urine.
Volume expansion would reset renal vasoactive tone toward a
renal vasodilatory state; the concomitant water diuresis would
dilute the concentration of contrast medium in the urine.
DR. BRIAN PEREIRA (Division of Nephrology, New England
Medical Center, Boston, Massachusetts): In your review, as in other
reviews of the literature, the risk factors for contrast-medium-
induced renal failure, other than the volume of dye administered,
are associated with structural or functional disturbances of the
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kidney. Is it fair to say that any renal structural or functional
disturbance increases the risk of contrast-induced ARF?
DR. SOLOMON: Radiocontrast-induced nephropathy represents
ischemic injury that is determined by the microcirculation of the
kidney. Any structural or functional alteration in that microcircu-
lation that predisposes to vasoconstriction increases the risk of
injury. I think this explains why older patients, patients with
diabetes mellitus, patients chronically treated with diuretics or
those who are volume depleted, and patients with congestive heart
failure are at increased risk of RCIN.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): My first question relates to the apparently
increased risk of acute renal insufficiency in patients with pre-
existing renal insufficiency. Based on physiologic principles, an
increase in serum creatinine would be a more sensitive indication
of a decreased GFR in patients whose baseline GFR is reduced.
Most of these studies, in fact, use an increase in serum creatinine
as a measure of the effect, so I question whether the true risk of
renal injury, expressed as a reduced GFR or some other marker,
is actually greater in people with a higher baseline serum creati-
nine; perhaps it is simply easier for us to detect renal injury in
these patients. Of course, clinically, it is most important to detect
acute renal injury in patients with pre-existing renal insufficiency.
Similarly, it is very important to prevent acute renal injury in these
patients. However, it might be misleading to expect the pathogen-
esis of injury to be different in people with renal insufficiency
versus people with normal kidneys.
I have another comment. I question the validity of some of the
studies of saline versus diuretics to prevent acute renal insuffi-
ciency. In principle, the volume of total-body water would affect
the rate of rise in serum creatinine for any given reduction in GFR
because creatinine is distributed in total-body water. Therefore
the rate of rise of serum creatinine is slower in patients with an
increase in total-body water. Studies using serum creatinine
concentration as the end point may be biased toward showing a
slower rise in serum creatinine in hydrated patients versus those
undergoing diuresis. Were the studies you described based on
clearance measurements or on the rate of rise in serum creati-
nine?
DR. SOLOMON: Let me address the second question first. All the
patients in our prospective trial received the same hydration
protocol and had replacement of all fluid losses. We used weight
as a measure of total-body water balance and the cumulative
intake and output record for each day following the angiographic
procedure. Our patients did not lose a significant amount of
weight (less than 1 kg), and any change in weight 24 hours after
angiography was similar in each group. Indeed, furosemide treat-
ment was still associated with an increase in serum creatinine
concentration when we looked only at the patients who gained
weight at 24 hours. The argument that the hydrated group had a
larger volume of distribution for creatinine relative to the group
who received mannitol or furosemide isn’t supported by the data.
I agree with you that a higher serum creatinine level prior to
contrast-medium exposure makes it easier to detect a subsequent
change and therefore to meet the definition of RCIN. Neverthe-
less, in animal experiments, in which glomerular filtration rate can
be accurately followed, prior renal insufficiency does increase the
development of radiocontrast-medium-induced nephropathy
[117].
In clinical practice, it is the rise in serum creatinine concentra-
tion that alerts the physician to the development of RCIN.
Although a 25% increase in serum creatinine (the definition of
RCIN used in most of the large trials) might not represent a major
functional derangement, it does result in an increase in length of
hospital stay for many patients. In hospitalized patients, RCIN
defined as a 25% increase in serum creatinine was associated with
increased morbidity and mortality [45].
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): You presented evidence supporting the use of lower
osmolar contrast agents for patients at high risk of contrast
nephrotoxicity. Yet you resisted the temptation of telling us
whether you would recommend the use of these agents in
high-risk patients. Is your reluctance driven by cost, or do you
sense that a similar benefit could be achieved by using half-normal
saline hydration? Have cost-benefit analyses been performed?
DR. SOLOMON: Cost is certainly an issue. However, our col-
leagues in radiology and cardiology have a number of justifica-
tions in addition to renal protection for using low-osmolality
agents. In our study, we observed an 11% incidence of RCIN with
a hydration protocol alone in a high-risk group of patients [28]. In
a large prospective trial comparing low- and high-osmolality
contrast media, the patients with renal insufficiency with and
without diabetes mellitus who received the low-osmolality con-
trast medium had a 21% incidence of RCIN [22]. So I would argue
that hydration is at least as efficacious as low-osmolality contrast
medium. The cost differential is influenced by a number of factors
in addition to the unit cost of contrast medium or saline. For
example, if the hydration protocol requires a prolonged period of
intravenous fluids prior to angiography, length of hospitalization
becomes an overriding cost concern. For this reason, it would be
very important to know whether the beneficial effects of intrave-
nous fluids can be realized over a shorter period, for example, 2 to
4 hours prior to contrast-medium exposure.
We performed a preliminary analysis of the potential cost
savings of using low-osmolality contrast medium in high-risk
patients, since there does not seem to be an advantage to
low-osmolality agents in patients with normal renal function [22].
We assumed an incidence of RCIN of 20%, which could be
reduced to 10% by the use of low-osmolality contrast medium
[95]. Thus, for every 10 patients treated with low-osmolality
contrast medium, there would be one less case of RCIN. The
additional cost of treating these 10 patients with low-osmolality
contrast media is roughly comparable to the cost of an extra 2 to
3 days of hospitalization in the patient who developed RCIN. Of
course, not all patients would need to stay in the hospital
following contrast-medium exposure, even those with RCIN.
Thus, in the case of outpatient radiologic studies, the use of
low-osmolality contrast medium might not be cost effective.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology, New
England Medical Center): I want to return to a question that Dr.
Harrington asked about the fractional excretion of sodium. Is it
low as well in patients who develop radiocontrast injury against a
background of chronic renal insufficiency?
DR. SOLOMON: Of the patients reported by Fang, 9 of 12 had
chronic renal insufficiency and a low fractional excretion of
sodium [13]. In the study by Schwab, the patients with pre-existing
renal insufficiency were not analyzed separately from the group
with baseline normal renal function. However, even in the pres-
ence of RCIN, fractional excretion of sodium remained less than
1% [15].
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DR. MADIAS: I was impressed with the results of your study [28],
as well as those of Weisberg and colleagues [55], showing no
protective effect of mannitol. Have any in-vitro studies suggested
an adverse interaction of mannitol with radiocontrast medium?
DR. SOLOMON: Mannitol is known to release atrial natriuretic
peptide [118]. One might speculate, particularly in view of the
adverse effect of exogenous vasodilators in patients with diabetes
[54], that the release of a potent endogenous vasodilator that
increases cortical blood flow might predispose to medullary
ischemia. This might explain the finding that mannitol decreases
medullary oxygen tension in the rat model [57]. The other
potential problem with mannitol is that it increases medullary
oxygen consumption by increasing delivery of sodium to the thick
ascending limb of Henle. The combination of a decrease in
medullary oxygen tension and an increase in medullary oxygen
consumption can lead to significant medullary ischemia and
injury.
DR. NICOLAOS ATHIENITES (Division of Nephrology, New England
Medical Center): You recommended hydration with saline before
contrast administration. A significant number of patients have
congestive heart failure or nephrotic syndrome due to diabetic
nephropathy. Would you monitor the urine output of those
patients? Is there any “target” urinary output before contrast
administration?
DR. SOLOMON: I’m not aware of any correlation with urine
output and the subsequent development of RCIN. I recommend
0.45% saline rather than 0.9% saline, and I explained our
justification for this choice previously. I am not worried about
giving 0.45% saline to patients with nephrotic syndrome for 12 or
more hours during and after contrast-medium exposure. The risk
of precipitating congestive heart failure in patients with left-
ventricular dysfunction requires close monitoring of such patients.
Congestive heart failure occurred in only one patient enrolled in
our study. In that patient, the symptoms were mild and quickly
reversed with nitropaste and diuresis and he was not included in
our data analysis.
DR. ANDREW KING (Division of Nephrology, New England Med-
ical Center): Animal studies suggest that inducing natriuresis and
diuresis protects the kidney from contrast-medium-induced dam-
age [96]. Yet in the human data you presented, the use of diuretics
increased the patient’s susceptibility to renal failure. That study
showed no difference in the patients’ weights [28], so it is unlikely
that overt volume contraction leads to the higher risk. Could you
speculate on the possible mechanisms of increased toxicity from
diuretics? The animal studies suggest that cells in the outer stripe
of the inner medulla are the most metabolically active; thus, one
would anticipate that inhibition with furosemide would be protec-
tive.
DR. SOLOMON: I too was surprised by the results of our study. As
you said, furosemide was protective in an animal model in which
oxygen tension in the medulla increased in response to furo-
semide [96]. However, the animal experiments were conducted
under conditions of volume depletion and prostaglandin inhibi-
tion. Under these conditions, which are associated with a decrease
in medullary blood flow, furosemide inhibition of active transport
can restore a critical balance between oxygen delivery and con-
sumption. In other settings, furosemide can produce a renal
vasodilatory effect (mediated by prostaglandins) occurring pri-
marily in the cortex [119]. Such cortical vasodilation might “steal”
blood from the medulla and thus contribute to toxicity during
exposure to the contrast medium. In addition, during the first few
hours after contrast-medium exposure, furosemide can produce
unrecognized intravascular volume depletion and activate medul-
lary vasoconstrictive mechanisms. We can miss these volume
changes when we look only at the cumulative 24-hour fluid
balance following contrast-medium exposure.
DR. HARRINGTON: Early in your discussion, you mentioned that
no patient who received less than 135 ml of contrast media
developed acute renal failure. That suggests that production of
renal damage is a step function, not a linear function, and that
something peculiar happens at the 135 ml to 150 ml dose range.
How do you account for that?
DR. SOLOMON: I wouldn’t put too much emphasis on an
absolute volume of contrast medium. Clearly, a dose-response
relationship does exist. A greater volume of contrast medium will
produce a greater increase in the osmolarity of blood perfusing
the kidney. It also will produce a greater osmotic diuresis with an
increase in sodium delivery to the loop of Henle and activation of
tubuloglomerular feedback mechanisms. Finally, the higher con-
centration of contrast medium can provoke more direct tubular
toxicity.
DR. MADIAS: Is there any evidence that the site of injection,
venous or arterial, makes a difference in the hemodynamic
response to radiocontrast agents?
DR. SOLOMON: Both intravenous and intra-arterial injection of
contrast medium can produce RCIN. The volume of contrast
medium is often greater with intravenous administration. An
increased incidence of acute renal failure was described with
intra-arterial contrast medium [17]. Intra-arterial administration
also is associated with an increased incidence of atheromatous
emboli; therefore, all the acute renal failure might not result from
RCIN. A direct comparison between equal volumes of intrave-
nous and intra-arterial administration and the incidence of RCIN
has not been reported.
DR. MADIAS: Did I understand you to say that the current
recommendation is that patients with normal renal function who
are using metformin should have it discontinued before receiving
a radiocontrast agent?
DR. SOLOMON: Yes, that is the recommendation. It is based on
concern that the development of RCIN increases the risk of
metformin-induced lactic acidosis. This association has been
documented in the literature [116].
DR. PEREIRA: I wanted to continue with the question that Dr.
Singh asked. What’s the difference in cost between a low-osmolar
contrast agent and the conventional agents? Second, could you
give me a dollar figure?
DR. SOLOMON: The difference in cost between low-osmolality
and high-osmolality agents is a factor of 10 to 20. High-osmolality
contrast medium is approximately $5 for a 50 ml bottle versus $50
to $100 for a similar volume of low-osmolality contrast medium.
DR. PEREIRA: If one takes into account an average hospital stay
of 3 to 5 days for contrast-induced ARF, and $1000 to $1500 per
day in hospital, is the use of the more expensive low-osmolar
contrast justified?
DR. SOLOMON: As I discussed previously, it would depend on
the clinical setting. For hospitalized patients, low-osmolar con-
trast medium might be cost-effective, because their costs would be
balanced by savings related to the extra days of hospitalization for
patients who develop RCIN. For outpatients, it is arguably more
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cost-effective to have visiting nurses or other home services
perform routine followup of patients.
DR. PEREIRA: But that doesn’t include the likelihood of irre-
versible renal failure and dialysis earlier than the patient should
have started dialysis.
DR. SOLOMON: You are right. That analysis does not take into
account more long-term adverse effects of contrast medium,
which are significant, particularly in hospitalized patients [45].
We’ve not had a comparison of adequate hydration versus low-
osmolality contrast medium. Certainly, the low-osmolality me-
dium is more convenient to use in many patients, and its use might
be justified even more in selected patients.
DR. PEREIRA: My final comment concerns a non-cost-related
issue. In your study, you brought the incidence of contrast-
medium-induced nephropathy down to 11%. You said that Rud-
nick also achieved 13%, but that if Rudnick had incorporated your
preventive measures, he probably could have reduced the 11% to
4% or 5%.
DR. SOLOMON: Of our patients who received only the hydration
protocol, RCIN occurred in 11%. The patients in the Rudnick
study were hydrated for as little as 4 hours before contrast-
medium exposure [22]. While the overall incidence of RCIN in
the low-osmolality contrast-medium group was 13% (versus 21%
in the high-osmolality contrast-medium group), the incidence of
RCIN was higher in the patients with renal insufficiency (21%
versus 36%, low- versus high-osmolality groups respectively).
Nearly one-half of the patients were receiving diuretics at the time
of exposure to contrast medium in that study. I can only speculate
as to whether discontinuation of diuretics and a longer period of
hydration might have decreased the incidence of RCIN in those
high-risk patients.
DR. SINGH: You hinted that diabetes mellitus and renal insuf-
ficiency might be connected to endothelial factors. Would you
elaborate on this? Is the connection one of renal hemodynamics?
Systemic hemodynamics? Do these patients have a more exagger-
ated biphasic response? Have studies looked at diabetic patients
with renal failure and those without renal failure to try to address
the difference? Clearly, the diabetic population is particularly
vunerable and probably the population that we should be focusing
on.
DR. SOLOMON: This is an excellent question and needs further
study. In the Weisberg study, patients with diabetes had a lower
total renal blood flow at any level of serum creatinine compared
to the non-diabetic patients. This reduction in renal blood flow
appears to be functional because it increased significantly both in
response to exogenous vasodilators and to contrast medium.
Indeed, renal blood flow increased to the same absolute level
following contrast medium and vasodilators as in the non-diabetic
patients [54]. This suggests that diabetic patients have a shift in
vasomotor tone toward increased vasoconstriction. I suspect that
this relative vasoconstriction is a reflection of generalized endo-
thelial-cell dysfunction in diabetes. Support for this hypothesis can
be found in studies of the vascular response of diabetics to
acetylcholine and ischemia [120]. These abnormalities also have
been reported in subjects with impaired glucose tolerance and in
first-degree relatives of diabetic patients [121].
DR. SVETLOZAR NATOV (Renal Fellow, Division of Nephrology,
New England Medical Center): Dr. Solomon, would you please give
us some insight on the phenomenon of acquired resistance to
acute renal failure? Animal studies have shown that during the
early recovery phase of ARF, tubules demonstrate increased
resistance to further injury [122]. How does this phenomenon
relate to humans? It is a common scenario to have a patient with
an increasing serum creatinine or established ARF secondary to
ATN who needs to undergo radiocontrast studies that are poten-
tially toxic to the kidneys. What is your practice in such cases?
DR. SOLOMON: While there might be experimental support for
the concept of acquired resistance to acute renal failure, I don’t
believe it has clinical relevance. Radiocontrast-medium-induced
nephropathy is an ischemic insult, and a second exposure to
contrast medium within a short time is a recognized risk factor for
RCIN [33]. Critically ill patients in intensive care units often have
prolonged acute renal failure as a result of multiple insults,
ischemic and nephrotoxic. This would not be expected if resis-
tance to acute renal failure were present. As a matter of practice,
therefore, we do not recommend elective contrast-medium expo-
sure in patients with a rising serum creatinine.
DR. MADIAS: Some evidence in animal models of nephrotoxic
acute renal failure—for example, that induced by glycerol, ura-
nium, or gentamicin—suggests that the first insult confers on the
kidney resistance to a second exposure to the same insult [122]. To
my knowledge, such protection has not been shown for ischemic
acute renal failure. One could speculate on a number of factors
that might be involved in this phenomenon. Dr. Solomon, does
radiocontrast medium administration trigger the heat-shock re-
sponse?
DR. SOLOMON: I am not aware of any published data on
heat-shock proteins and contrast media. In the case of nephro-
toxin-induced acute renal failure, we might speculate that active
transport mechanisms necessary for cellular uptake of the toxin
are impaired following an initial insult. Some resistance to a
second insult is thus present. However, I am not aware that there
is an analogous resistance in the case of ischemia. As I indicated,
we see too many clinical examples in which multiple renal insults
result in more severe renal dysfunction.
Reprint requests to Dr. R. Solomon, Joslin Diabetes Center, One Joslin
Place, Boston, Massachusetts, 02215, USA
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